| Literature DB >> 33897771 |
Yunshu Gao1, Jiahua Xu2, Hongwei Li2, Yi Hu1, Guanzhen Yu2.
Abstract
It is reported that microRNAs (miRNA) have paramount functions in many cellular biological processes, development, metabolism, differentiation, survival, proliferation, and apoptosis included, some of which are involved in metastasis of tumors, such as melanoma. Here, three metastasis-associated miRNAs, miR-18a-5p (upregulated), miR-155-5p (downregulated), and miR-93-5p (upregulated), were identified from a total of 63 different expression miRNAs (DEMs) in metastatic melanoma compared with primary melanoma. We predicted 262 target genes of miR-18a-5p, 904 miR-155-5p target genes, and 1220 miR-93-5p target genes. They participated in pathways concerning melanoma, such as TNF signaling pathway, pathways in cancer, FoxO signaling pathway, cell cycle, Hippo signaling pathway, and TGF-beta signaling pathway. We identified the top 10 hub nodes whose degrees were higher for each survival-associated miRNA as hub genes through constructing the PPI network. Using the selected miRNA and the hub genes, we constructed the miRNA-hub gene network, and PTEN and CCND1 were found to be regulated by all three miRNAs. Of note, miR-155-5p was obviously downregulated in metastatic melanoma tissues, and miR-18a-5p and miR-93-5p were obviously regulated positively in metastatic melanoma tissues. In validating experiments, miR-155-5p's overexpression inhibited miR-18a-5p's and miR-93-5p's expression, which could all significantly reduce SK-MEL-28 cells' invasive ability. Finally, miR-93-5p and its potential target gene UBC were selected for further validation. We found that miR-93-5p's inhibition could reduce SK-MEL-28 cell's invasive ability through upregulated the expression of UBC, and the anti-invasive effect was reserved by downregulation of UBC. The results show that the selected three metastasis-associated miRNAs participate in the process of melanoma metastasis via regulating their target genes, providing a potential molecular mechanism for this disease.Entities:
Keywords: MiR-93-5p; melanoma; metastasis; miR-155-5p; miR-18a-5p; miRNA
Year: 2021 PMID: 33897771 PMCID: PMC8063111 DOI: 10.3389/fgene.2021.663110
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Kaplan–Meier survival curve of selected miRNA in melanoma. (A) for miR-155-5p; (B) for miR-18a-5p; (C) for miR-93-5p.
Figure 2The analysis of GO functions and KEGG pathway for three survival-associated miRNAs target genes. (A,D,G) The top 10 enriched biological processes of miR-155-5p, miR-18a-5p, and miR-93-5p; (B,E,H) The top 10 enriched cellular components of miR-155-5p, miR-18a-5p, and miR-93-5p; (C,F,I) The top 10 enriched molecular function of miR-155-5p, miR-18a-5p, and miR-93-5p. (J–L) KEGG pathway analysis for miR-155-5p, miR-18a-5p, and miR-93-5p. The black lines stand for gene count and the red lines stand for–log10 (P-value).
Hub genes identified in the PPI interaction.
| hsa-miR-155-5p | ||
| AKT1 | 172 | Pathways in cancer, TNF signaling pathway, FoxO signaling pathway, Signaling pathways regulating pluripotency of stem cells |
| EGFR | 141 | Pathways in cancer, FoxO signaling pathway |
| MYC | 140 | Pathways in cancer, Signaling pathways regulating pluripotency of stem cells |
| CTNNB1 | 111 | Pathways in cancer, Signaling pathways regulating pluripotency of stem cells |
| JUN | 110 | Pathways in cancer, TNF signaling pathway, T cell receptor signaling pathway |
| IL6 | 107 | Pathways in cancer, TNF signaling pathway, FoxO signaling pathway |
| PTEN | 107 | Pathways in cancer, FoxO signaling pathway |
| CCND1 | 106 | Pathways in cancer, FoxO signaling pathway |
| STAT3 | 105 | Pathways in cancer, FoxO signaling pathway, Signaling pathways regulating pluripotency of stem cells |
| CASP3 | 98 | Pathways in cancer, TNF signaling pathway |
| hsa-miR-18a-5p | ||
| TP53 | 56 | Cell cycle, Proteoglycans in cancer, Pathways in cancer, Pathways in cancer, hyroid hormone signaling pathway |
| UBC | 46 | NA |
| CCND1 | 34 | Cell cycle, FoxO signaling pathway, Hippo signaling pathway, Proteoglycans in cancer, Pathways in cancer, Thyroid hormone signaling pathway |
| PTEN | 32 | FoxO signaling pathway, Pathways in cancer |
| CDC20 | 29 | Cell cycle |
| ESR1 | 29 | Proteoglycans in cancer, Thyroid hormone signaling pathway |
| CCT6A | 21 | NA |
| ATM | 21 | Cell cycle, FoxO signaling pathway |
| SMAD2 | 21 | Cell cycle, FoxO signaling pathway, Hippo signaling pathway, Pathways in cancer |
| SMAD4 | 20 | Cell cycle, FoxO signaling pathway, Hippo signaling pathway, Pathways in cancer |
| hsa-miR-93-5p | ||
| UBC | 177 | NA |
| RPS27A | 176 | NA |
| GAPDH | 150 | NA |
| MYC | 144 | Pathways in cancer, TGF-beta signaling pathway |
| MAPK1 | 116 | Pathways in cancer, TGF-beta signaling pathway |
| HSPA8 | 113 | NA |
| PTEN | 113 | Pathways in cancer |
| JUN | 111 | Pathways in cancer |
| CCND1 | 104 | Pathways in cancer |
| POLR2A | 97 | NA |
Figure 3The regulative network between three selected miRNAs and hub genes.
Figure 4The expression and prognostic functions of miR-155-5p, miR-18a-5p, and miR-93-5p in melanoma metastasis. (A–C) miR-155-5p's, miR-18a-5p's, and miR-93-5p's expression in metastatic melanoma tissues (n = 15) and primary tissues (n = 18). (D) Validation of miR-155-5p expression, miR-18a-5p expression, and miR-93-5p expression in transfected SK-MEL-28 cells. (E) Validation of UBC expression in transfected SK-MEL-28 cells. (F) SK-MEL-28 transfected with miR-155-5p, miR-18a-5p inhibitor, or miR-93-5p inhibitor invaded less vs. control cancer cells. ***P < 0.001, **P < 0.01, *P < 0.05. PM, primary melanoma; MM, metastatic melanoma.
Figure 5Inhibition of miR-93-5p could reduce SK-MEL-28 cells' invasive ability through UBC. (A) The miR-93-5p and UBC expression data of 449 melanoma patients from ENCORI. We observed the inverse correlation with statistical significance between miR-93-5p and UBC mRNA. (B) Diagram of UBC 3'UTR including 1 putative conserved target sites for miR-93-5p, recognized through making use of the TargetScan database. (C) Results of luciferase reporter experiments in SK-MEL-28 cells, with co-transfection of wt or mt 3'UTR and miR mimic, as shown. (D) The protein expression of UBC in SK-MEL-28 cells transfected with miR-93-5p. (E) SK-MEL-28 transfected with miR-93-5p inhibitor invaded less vs. control cancer cells, and the anti-invasive effect by miR-93-5p inhibitor was reduced when the expression of UBC was decreased by its siRNA. **P < 0.01 miR-93-5p inhibitor vs. control, ##P < 0.01 miR-93-5p inhibitor vs. miR-93-5p inhibitor+siUBC.
Figure 6A schematic illustration of the metastasis-associated microRNAs in melanoma.